Buy Paclitax : Paclitaxel 260 Mg Injection Online

Description

Description: Paclitax is a pharmaceutical product manufactured by Cipla Ltd. It contains Paclitaxel as its active substance and is primarily used in the treatment of various types of cancer, including breast cancer, ovarian cancer, lung cancer, and Kaposi’s sarcoma. Paclitax is available in injectable form, with each vial containing 260 mg of Paclitaxel.

Active Substance: Paclitaxel is a cytotoxic chemotherapy medication that belongs to the class of taxanes. It works by inhibiting microtubule disassembly during cell division, leading to the stabilization of microtubules and the disruption of mitotic spindle function. This ultimately results in cell cycle arrest and apoptosis (programmed cell death) of cancer cells. Paclitaxel is used in the treatment of various solid tumors, both as a single-agent therapy and in combination with other chemotherapy drugs or targeted therapies.

Manufacturer: Paclitax is manufactured by Cipla Ltd, a reputable pharmaceutical company known for its commitment to producing high-quality medications. Cipla Ltd adheres to stringent manufacturing standards to ensure the safety, efficacy, and consistency of its products.

Strength and Formulation: Each vial of Paclitax contains 260 mg of Paclitaxel as the active ingredient. The injectable formulation is supplied as a sterile, non-aqueous solution for intravenous infusion. The concentration of Paclitaxel in the solution is typically adjusted to achieve the desired dosage based on the patient’s body surface area and the specific cancer being treated.

Indications: Paclitax (Paclitaxel) is indicated for the treatment of various cancers, including:

1. Breast cancer, including metastatic or locally advanced breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy.
2. Ovarian cancer, including metastatic or locally advanced epithelial ovarian cancer in combination with cisplatin.
3. Non-small cell lung cancer (NSCLC), including locally advanced or metastatic disease in patients who are not candidates for potentially curative surgery or radiation therapy.
4. AIDS-related Kaposi’s sarcoma, in patients with advanced or refractory disease.

Usage and Dosage: The recommended dosage of Paclitax (Paclitaxel) may vary depending on factors such as the patient’s medical condition, treatment response, and tolerability. It is usually administered intravenously over 3 to 24 hours, depending on the specific protocol and infusion rate. The dosage and schedule of Paclitaxel treatment are determined by the prescribing healthcare provider based on the patient’s individualized treatment plan.

Storage Conditions: Paclitax vials should be stored according to the manufacturer’s instructions, typically in a cool, dry place, away from direct sunlight, and at room temperature. The solution should be protected from freezing and should be inspected visually for particulate matter and discoloration before use. Proper storage helps maintain the stability and efficacy of the medication.

Patients should consult their healthcare provider for personalized information regarding the use of Paclitax, including dosage adjustments, potential side effects, and monitoring during treatment. Regular follow-up appointments are essential to evaluate treatment response and manage any adverse reactions.